Indication
CD20-Positive Lymphoid Malignancies
1 clinical trial
2 products
Product
rituximabClinical trial
A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Rituximab in Subjects With CD20-positive Lymphoid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-05-03
Product
ABT-263